NEW YORK (GenomeWeb News) – Thomas Weisel Partners analyst Peter Lawson upgraded his rating on Genomic Health's stock from "market weight" to "overweight," citing the firm's relatively low valuation and potential upside.

Lawson said in a research note published last night that Genomic Health is trading below its broader peer group and such firms as Gen-Probe, Luminex, Cepheid, and Myriad Genetics. In addition, he said that a new colon cancer assay that is expected to be launched in early 2010 "will add significant value to current diagnostic workups."

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

The Asbury Park Press reports on the startup Genomic Prediction's test to determine an embryo's risk of disease.

NPR reports that with medical data being big business, some companies want to get patients involved.

In PNAS this week: optical mapping allows glimpse of structural variants, disease-linked GATA2 mutations boosts its protein activity, and more.

Senator Elizabeth Warren (D-Mass.) has released the results of a genetic ancestry analysis, the Boston Globe reports.

Oct
23
Sponsored by
PerkinElmer

This webinar will address a range of methods for optimizing small RNA library preparation.

Nov
05
Sponsored by
Sophia Genetics

With the Next Generation Sequencing (NGS), genomes sequencing has been democratized over the last decades with the detection of genomic alterations, thus replacing Sanger sequencing.

Nov
29
Sponsored by
Schott

This webinar will discuss how understanding the relative performance characteristics of glass and polymer substrates for in vitro diagnostic applications such as microarrays and microfluidics can help to optimize diagnostic performance.